Skip to content

Released Nov 10, 2022, before the open

10-Q filed Nov 10, 2022, 41 days after period end · 0001785530-22-000038

Q3 2022 · 10-Q
Revenue—
Net Income-$11.94MN/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$0.40N/M vs Q3 2021N/M vs Q2 2022
Operating Income-$12,539,000N/M
Operating Cash Flowderived-$14,472,000N/M
Free Cash Flowderived-$16,426,000N/M

What the release said

The release

Same quarter

MetricQ3 2022Q3 2021Q3 2020
Net Income-$11.94M-$13.76M-$6.07M
EPS Diluted-$0.40-$0.51-$6.61

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR